Redbiotec is pleased to announce that the project started with Merck Sharp & Dohme Corp. (NJ, USA) in October 2011, in which Redbiotec applies its proprietary technology platform rePAX® to an undisclosed discovery area, has reached a first milestone successfully and was therefore extended. We look forward to the ongoing collaboration with Merck!